Secured Retirement Advisors LLC Invests $413,000 in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Secured Retirement Advisors LLC has invested $413,000 in Zimmer Biomet Holdings, Inc., acquiring 4,525 shares during the second quarter.
• Zimmer Biomet reported a Q2 EPS of $2.07, beating estimates, with revenue of $2.08 billion, marking a 7.0% year-over-year increase.
• The company announced a quarterly dividend of $0.24 per share, with a yield of 1.0%, to be paid on October 31st.

Secured Retirement Advisors LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,525 shares of the medical equipment provider's stock, valued at approximately $413,000.

Other hedge funds have also recently modified their holdings of the company. Garde Capital Inc. purchased a new position in shares of Zimmer Biomet in the first quarter worth $29,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet during the first quarter valued at $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet during the first quarter valued at $30,000. Accent Capital Management LLC bought a new position in Zimmer Biomet during the first quarter valued at $35,000. Finally, Cullen Frost Bankers Inc. lifted its position in Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 305 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Up 0.3%

NYSE ZBH opened at $99.12 on Wednesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The company has a market capitalization of $19.63 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.67. The company's 50-day simple moving average is $101.01 and its two-hundred day simple moving average is $98.54. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.70% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on ZBH shares. Weiss Ratings reiterated a "hold (c-)" rating on shares of Zimmer Biomet in a research report on Saturday, September 27th. Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a "buy" rating and a $130.00 target price for the company. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Finally, Royal Bank Of Canada raised their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $112.89.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.